Synthetic Monoclonal Antibody Designed for Novel SARS-nCoV-2 Spike-S1 Protein Antigenic Targeted Epitope of Receptor Binding Domain Inhibit to Prevent Viral Entry

Severe acute respiratory syndrome (SARS) is developing disease caused by novel coronavirus (COVID19). This situation has urgently prompted many pharma and R&D research companies and public research health sectors to concentrate their efforts on research for effective therapeutics. SARS-nCoV-2 as a spike (S) protein was a targeted for the development of monoclonal antibody and therapeutics for the prevention and treatment. We developed monoclonal antibody by deep mutational scanning to characterize the effects of mutations in an antibody variable fragment on its based on expression levels, specificity, stability, and affinity for antigenic specific epitope to the Spike-S-RBD. Further to make this antibody multipoint core mutations to improve contacts between specific Fv light and heavy chains to the targeted antigen of RBD. This antibody combined enhancing mutations yielding with higher binding affinity and substantially improved stability in between RBD and antibody. Overall, this antibody may well prevent into the cell interaction with RBD-hACE2 to viral entry and prevention. SARS-nCoV-Spike-S monoclonal antibodies potently inhibited SARS-nCoV-2-Spike-S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited based upon vaccination.